<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE root>
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="research-article" dtd-version="1.2" xml:lang="en"><front><journal-meta><journal-id journal-id-type="publisher-id">Russian Journal of Pediatric Surgery, Anesthesia and Intensive Care</journal-id><journal-title-group><journal-title xml:lang="en">Russian Journal of Pediatric Surgery, Anesthesia and Intensive Care</journal-title><trans-title-group xml:lang="ru"><trans-title>Российский вестник детской хирургии, анестезиологии и реаниматологии</trans-title></trans-title-group></journal-title-group><issn publication-format="print">2219-4061</issn><issn publication-format="electronic">2587-6554</issn><publisher><publisher-name xml:lang="en">Eco-Vector</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">1822</article-id><article-id pub-id-type="doi">10.17816/psaic1822</article-id><article-categories><subj-group subj-group-type="toc-heading" xml:lang="en"><subject>Original Study Articles</subject></subj-group><subj-group subj-group-type="toc-heading" xml:lang="ru"><subject>Оригинальные исследования</subject></subj-group><subj-group subj-group-type="article-type"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title xml:lang="en">Neutrophil CD10 and CD16 as markers of generalized infection development in newborns</article-title><trans-title-group xml:lang="ru"><trans-title>CD10 и CD16 нейтрофилов как маркеры развития генерализованной инфекции у новорожденных</trans-title></trans-title-group><trans-title-group xml:lang="zh"><trans-title>CD10和CD16中性粒细胞作为新生儿全身性感染发展的标志物</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-6649-853X</contrib-id><contrib-id contrib-id-type="spin">6466-5680</contrib-id><name-alternatives><name xml:lang="en"><surname>Obraztsov</surname><given-names>Igor V.</given-names></name><name xml:lang="ru"><surname>Образцов</surname><given-names>Игорь Владимирович</given-names></name><name xml:lang="zh"><surname></surname><given-names></given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>MD, Cand. Sci. (Medicine)</p></bio><bio xml:lang="ru"><p>кандидат медицинских наук</p></bio><email>obraztsoviv@zdrav.mos.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Obraztsova</surname><given-names>Anastasiia A.</given-names></name><name xml:lang="ru"><surname>Образцова</surname><given-names>Анастасия Александровна</given-names></name><name xml:lang="zh"><surname></surname><given-names></given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>MD</p></bio><email>obraztsovaaa@zdrav.mos.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0009-0001-5942-2430</contrib-id><name-alternatives><name xml:lang="en"><surname>Voronina</surname><given-names>Oksana V.</given-names></name><name xml:lang="ru"><surname>Воронина</surname><given-names>Оксана Викторовна</given-names></name><name xml:lang="zh"><surname></surname><given-names></given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>MD</p></bio><email>tkachukviktor601@gmail.com</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-9409-7832</contrib-id><contrib-id contrib-id-type="spin">6346-9181</contrib-id><name-alternatives><name xml:lang="en"><surname>Chernikova</surname><given-names>Ekaterina A.</given-names></name><name xml:lang="ru"><surname>Черникова</surname><given-names>Екатерина Алексеевна</given-names></name><name xml:lang="zh"><surname></surname><given-names></given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><email>krasenkova.ea@gmail.com</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0009-0003-1353-1441</contrib-id><contrib-id contrib-id-type="spin">4509-8053</contrib-id><name-alternatives><name xml:lang="en"><surname>Mishchenko</surname><given-names>Anastasiya Yu.</given-names></name><name xml:lang="ru"><surname>Мищенко</surname><given-names>Анастасия Юрьевна</given-names></name><name xml:lang="zh"><surname></surname><given-names></given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>MD</p></bio><email>nasta.tlt@mail.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-3948-8491</contrib-id><contrib-id contrib-id-type="spin">2205-4033</contrib-id><name-alternatives><name xml:lang="en"><surname>Gordukova</surname><given-names>Maria A.</given-names></name><name xml:lang="ru"><surname>Гордукова</surname><given-names>Мария Александровна</given-names></name><name xml:lang="zh"><surname></surname><given-names></given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>MD, Cand. Sci. (Medicine)</p></bio><bio xml:lang="ru"><p>кандидат биологических наук</p></bio><email>gordukovama@zdrav.mos.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-7325-6045</contrib-id><contrib-id contrib-id-type="spin">9997-6197</contrib-id><name-alternatives><name xml:lang="en"><surname>Davydova</surname><given-names>Nataliia V.</given-names></name><name xml:lang="ru"><surname>Давыдова</surname><given-names>Наталия Владимировна</given-names></name><name xml:lang="zh"><surname></surname><given-names></given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>MD, Cand. Sci. (Medicine)</p></bio><bio xml:lang="ru"><p>кандидат медицинских наук</p></bio><email>nata1902@yandex.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-7861-6778</contrib-id><contrib-id contrib-id-type="spin">5560-6679</contrib-id><name-alternatives><name xml:lang="en"><surname>Zhirkova</surname><given-names>Julia V.</given-names></name><name xml:lang="ru"><surname>Жиркова</surname><given-names>Юлия Викторовна</given-names></name><name xml:lang="zh"><surname></surname><given-names></given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>MD, Dr. Sci. (Medicine), Associate Professor</p></bio><bio xml:lang="ru"><p>доктор медицинских наук, профессор</p></bio><email>zhirkova@mail.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-9087-1656</contrib-id><contrib-id contrib-id-type="spin">6374-0484</contrib-id><name-alternatives><name xml:lang="en"><surname>Korsunskiy</surname><given-names>Anatoly A.</given-names></name><name xml:lang="ru"><surname>Корсунский</surname><given-names>Анатолий Александрович</given-names></name><name xml:lang="zh"><surname></surname><given-names></given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>MD, Dr. Sci. (Medicine), Professor</p></bio><bio xml:lang="ru"><p>доктор медицинских наук, профессор</p></bio><email>dr_kaa@mail.ru</email><xref ref-type="aff" rid="aff3"/><xref ref-type="aff" rid="aff4"/></contrib></contrib-group><aff-alternatives id="aff1"><aff><institution xml:lang="en">Speransky Children’s City Clinical Hospital No. 9</institution></aff><aff><institution xml:lang="ru">Детская городская клиническая больница № 9 им. Г.Н. Сперанского</institution></aff><aff><institution xml:lang="zh"></institution></aff></aff-alternatives><aff-alternatives id="aff2"><aff><institution xml:lang="en">Pirogov Russian National Research Medical University</institution></aff><aff><institution xml:lang="ru">Российский национальный исследовательский медицинский университет им. Н.И. Пирогова</institution></aff><aff><institution xml:lang="zh"></institution></aff></aff-alternatives><aff-alternatives id="aff3"><aff><institution xml:lang="en">Speransky Children’s City Clinical Hospital No. 9</institution></aff><aff><institution xml:lang="ru">Детская городская клиническая больница № 9 им. Г.Н. Сперанского</institution></aff></aff-alternatives><aff-alternatives id="aff4"><aff><institution xml:lang="en">Sechenov First Moscow State Medical University</institution></aff><aff><institution xml:lang="ru">Первый Московский государственный медицинский университет им. И.М. Сеченова (Сеченовский Университет)</institution></aff></aff-alternatives><pub-date date-type="pub" iso-8601-date="2024-09-28" publication-format="electronic"><day>28</day><month>09</month><year>2024</year></pub-date><volume>14</volume><issue>3</issue><issue-title xml:lang="en"/><issue-title xml:lang="ru"/><issue-title xml:lang="zh"/><fpage>369</fpage><lpage>380</lpage><history><date date-type="received" iso-8601-date="2024-06-06"><day>06</day><month>06</month><year>2024</year></date><date date-type="accepted" iso-8601-date="2024-08-13"><day>13</day><month>08</month><year>2024</year></date></history><permissions><copyright-statement xml:lang="en">Copyright ©; 2024, Eco-Vector</copyright-statement><copyright-statement xml:lang="ru">Copyright ©; 2024, Эко-Вектор</copyright-statement><copyright-statement xml:lang="zh">Copyright ©; 2024,</copyright-statement><copyright-year>2024</copyright-year><copyright-holder xml:lang="en">Eco-Vector</copyright-holder><copyright-holder xml:lang="ru">Эко-Вектор</copyright-holder><ali:free_to_read xmlns:ali="http://www.niso.org/schemas/ali/1.0/"/><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/">https://creativecommons.org/licenses/by-nc-nd/4.0</ali:license_ref></license></permissions><self-uri xlink:href="https://rps-journal.ru/jour/article/view/1822">https://rps-journal.ru/jour/article/view/1822</self-uri><abstract xml:lang="en"><p><bold>BACKGROUND</bold>:<bold> </bold>Neonatal sepsis remains a critical concern. Thus, predictors of infection development and generalization should be determined.</p> <p><bold>AIM:</bold> This study aimed to determine novel neutrophil surface biomarkers for early prediction of the infections in newborns.</p> <p><bold>MATERIALS AND METHODS:</bold> This observational, single-center, prospective, selective, uncontrolled, unblinded experimental study included 261 newborns, with a mean postconceptual age of 38.7 (38.4–39.0) weeks and a mean gestation age of 38.0 (37.7–38.2) weeks. Blood samples were collected into vacutainers on hospitalization day 1. Patients were enrolled between April 2022 and December 2023. The primary endpoints were length of stay in the ICU and total length of hospitalization in patients with normal and decreased values of CD16 and CD10 neutrophils and HLA-DR monocytes. The expression of CD16 on CD62L<sup>high</sup> neutrophils, total neutrophil CD10, and monocyte HLA-DR were evaluated by flow cytometry.</p> <p><bold>RESULTS:</bold> We assessed infants in the “control” (n = 96), “localized infection” (n = 95), and “generalized infection” (n = 70) subgroups. In all patients, a decrease in CD16 was associated with an increase in the median ICU stay from 4 to 8 days (p = 9.33 × 10<sup>–8</sup>) and total stay from 14 to 22 days (p = 1.58 × 10<sup>–7</sup>). A decrease in CD10 was associated with an increase in median ICU stay from 4 to 8 days (p = 3.01 × 10<sup>–6</sup>) and in the total stay from 14 to 19 days (p = 2.78 × 10<sup>–5</sup>). A decrease in monocytic HLA-DR was associated with a longer ICU and total hospital stay: 4 vs 8 days (p = 7.16 × 10<sup>–5</sup>) and 14 vs 21 days (p = 4.03 × 10<sup>–5</sup>), respectively. The median ICU stay in patients with a decrease in CD16 but normal CD10 was 4 days, whereas a decrease in both indicators was associated with prolonged hospital stay to 11 days (p = 2.13 × 10<sup>–5</sup>). The median hospital stay in patients with decreased CD16 but normal CD10 was 16 days, whereas the drop of both markers was related with increase of hospitalization stay to 23 days (p = 3.36 × 10<sup>–6</sup>). In the “localized infection” subgroup, low CD16 was associated with an increased median ICU stay from 4 to 6 days (p = 0.010) and the median hospital stay from 13 to 19 days (p = 4.14 × 10<sup>–4</sup>). In the “generalized infection” subgroup, decreased CD10 was related with prolongation of the median ICU stay from 7 to 11 days (p = 0.011) and the median total duration of hospitalization from 19 to 27 days (p = 0.037).</p> <p><bold>CONCLUSIONS:</bold><bold> </bold>A decrease in CD10 and CD16 on the neutrophils at the start of clinical is an unfavorable prognostic factor of infectious and septic complications in newborns.</p></abstract><trans-abstract xml:lang="ru"><p><bold>Актуальность. </bold>Проблема неонатального сепсиса сегодня сохраняет свою актуальность, поэтому целесообразен поиск новых ранних предикторов развития и генерализации инфекции.</p> <p><bold>Цель — </bold>определить особенности фенотипа нейтрофилов, обладающие прогностическим значением при развитии инфекционных процессов у новорожденных.</p> <p><bold>Материалы и методы.</bold> В рамках настоящего обсервационного одноцентрового проспективного выборочного неконтролируемого неослепленного экспериментального исследования обследован 261 новорожденный в период с 2022 по 2023 г. в подгруппах «Контроль» (<italic>n</italic> = 96), «Локализованная инфекция» (<italic>n</italic> = 95) и «Генерализованная инфекция» (<italic>n</italic><italic> </italic>= 70). Средний постконцептуальный возраст обследованных составил 38,7 (38,4–39,0) нед., срок гестации 38,0 (37,7–38,2) нед. Образцы периферической венозной крови отбирали в вакутейнер для анализа в первые сутки госпитализации. Первичные конечные точки — длительность лечения в отделении реанимации и интенсивной терапии (ОРИТ) и в стационаре в зависимости от фенотипа нейтрофилов (нормальный или пониженный уровень мембранных белков CD16 и CD10) и HLA-DR моноцитов. Оценка экспрессии CD16 на CD62L-позитивных нейтрофилах, CD10 на всех нейтрофилах и HLA-DR на моноцитах выполнена методом проточной цитометрии.</p> <p><bold>Результаты.</bold> Снижение уровня CD16 связано с увеличением медианы длительности лечения в ОРИТ с 4 до 8 дней (<italic>р</italic> = 9,33×10<sup>–8</sup>), в стационаре — с 14 до 22 (<italic>р</italic> = 1,58×10<sup>–7</sup>). Снижение уровня CD10 ассоциировано с более длительным пребыванием в ОРИТ (4 против 8 дней; <italic>р</italic> = 3,01×10<sup>–6</sup>) и в стационаре — 14 против 19 дней (<italic>р</italic> = 2,78×10<sup>–5</sup>). Низкий уровень HLA-DR также связан с увеличением медианы срока лечения как в ОРИТ, так и в стационаре: 4 против 8 дней, <italic>р</italic> = 7,16×10<sup>–5</sup>, и 14 против 21 дня, <italic>р</italic> = 4,03×10<sup>–5</sup> соответственно. Медиана срока лечения в ОРИТ при снижении уровня CD16 при нормальном CD10 составил 4 дня, при снижении уровней обоих показателей — 11 дней (<italic>р</italic> = 2,13×10<sup>–5</sup>). Медиана общей длительности госпитализации у пациентов со снижением CD16 при нормальном CD10 составила 16 дней, а при снижении обоих показателей — 23 дня (<italic>р</italic> = 3,36×10<sup>–6</sup>). В подгруппе «Локализованная инфекция» снижение CD16 связано с увеличением медианы пребывания в ОРИТ с 4 до 6 дней (<italic>р</italic> = 0,010), общей длительности госпитализации — с 13 до 19 дней (<italic>р </italic>= 4,14×10<sup>–4</sup>). Снижение CD10 в этой подгруппе ассоциировано с увеличением медианы пребывания в ОРИТ с 7 до 11 дней (<italic>р</italic> = 0,011) и общей длительности госпитализации — с 19 до 27 дней (<italic>р</italic> = 0,037).</p> <p><bold>Заключение. </bold>Снижение уровня мембранных белков CD10 и CD16 нейтрофилов в первые сутки лечения в стационаре является неблагоприятным прогностическим фактором генерализации инфекции у новорожденных.</p></trans-abstract><trans-abstract xml:lang="zh"><p>现实性。新生儿脓毒症的问题至今仍然十分重要，因此寻找新的早期预测因子以识别感染的发展和扩散具有重要意义。</p> <p>目的。确定在新生儿感染过程中具有预后价值的中性粒细胞表型特征。</p> <p>材料和方法。在本研究中，进行了一项观察性单中心前瞻性选择性非对照实验，研究对象为261名新生儿，时间范围为2022年至2023年，分为“对照”组（n = 96）、 “局部感染”组（n = 95）和“全身感染”组（n = 70）。调查对象的平均后概念年龄为38.7周（范围38.4–39.0周），妊娠周数为38.0周（范围37.7–38.2周）。在住院的第一天，从外周静脉采集血样以进行分析。</p> <p>结果。CD16水平的降低与重症监护（ОРИТ）治疗时间的延长相关，从4天增加到8天（p = 9.33×10<sup>-8</sup>）， 住院时间从14天延长至22天（p = 1.58×10<sup>-7</sup>）。CD10水平的降低同样与ОРИТ的治疗时长延长有关，从4天增加到8天（p = 3.01×10<sup>-6</sup>），住院时间则从14天延长至19天（p = 2.78×10<sup>-5</sup>）。低水平的HLA-DR也与ОРИТ及住院时间的延长相关：分别为4天对8天（p = 7.16×10<sup>-5</sup>）和14天对21天（p = 4.03×10<sup>-5</sup>）。在正常CD10水平下，CD16水平降低的患者在ОРИТ的治疗时间为4天，而当两个指标均降低时，治疗时间则为11天（p = 2.13×10<sup>-5</sup>）。在CD16降低且CD10正常的患者中，住院总时长的中位数为16天，而在两者均降低的情况下则为23天（p = 3.36×10<sup>-6</sup>）。在“局部感染”组中，CD16水平降低与ОРИТ住院时间的中位数增加相关，从4天延长至6天（p = 0.010），而总住院时间则从13天延长至19天（p = 4.14×10<sup>-4</sup>）。在该子组中，CD10水平降低与ОРИТ住院时间的中位数增加有关，从7天延长至11天（p = 0.011），总住院时间则从19天延长至27天（p = 0.037）。</p> <p>结论。中性粒细胞膜蛋白CD10和CD16水平在住院治疗的第一天降低，成为新生儿全身性感染的一个不良预后因素。这一发现提示，监测这两个标志物的表达可能有助于早期识别感染进展风险，从而改善临床管理和治疗策略。</p></trans-abstract><kwd-group xml:lang="en"><kwd>CD10</kwd><kwd>CD16</kwd><kwd>CD62L</kwd><kwd>HLA-DR</kwd><kwd>neutrophils</kwd><kwd>monocytes</kwd><kwd>neonatal sepsis</kwd><kwd>children</kwd></kwd-group><kwd-group xml:lang="ru"><kwd>CD10</kwd><kwd>CD16</kwd><kwd>CD62L</kwd><kwd>HLA-DR</kwd><kwd>нейтрофилы</kwd><kwd>моноциты</kwd><kwd>неонатальный сепсис</kwd><kwd>дети</kwd></kwd-group><kwd-group xml:lang="zh"><kwd>CD10</kwd><kwd>CD16</kwd><kwd>CD62L</kwd><kwd>HLA-DR</kwd><kwd>中性粒细胞</kwd><kwd>单核细胞</kwd><kwd>新生儿脓毒症</kwd><kwd>儿童</kwd></kwd-group><funding-group><award-group><funding-source><institution-wrap><institution xml:lang="ru">Автономная некоммерческая организация «Московский центр инновационных технологий в здравоохранении»</institution></institution-wrap><institution-wrap><institution xml:lang="en">Autonomous non-profit organization "Moscow Center for Innovative Technologies in Healthcare"</institution></institution-wrap></funding-source><award-id>1712-3/22</award-id></award-group></funding-group></article-meta></front><body></body><back><ref-list><ref id="B1"><label>1.</label><citation-alternatives><mixed-citation xml:lang="en">Singer M, Deutschman CS, Seymour CW, et al. The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3). JAMA. 2016;315(8):801–810. doi: 10.1001/jama.2016.0287</mixed-citation><mixed-citation xml:lang="ru">Singer M., Deutschman C.S., Seymour C.W., et al. The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3) // JAMA. 2016. Vol. 315, N 8. P. 801–810. doi: 10.1001/jama.2016.0287</mixed-citation></citation-alternatives></ref><ref id="B2"><label>2.</label><citation-alternatives><mixed-citation xml:lang="en">Shane AL, Sánchez PJ, Stoll BJ. Neonatal sepsis. Lancet. 2017;390(10104):1770–1780. doi: 10.1016/S0140-6736(17)31002-4</mixed-citation><mixed-citation xml:lang="ru">Shane A.L., Sánchez P.J., Stoll B.J. Neonatal sepsis // Lancet. 2017. Vol. 390, N 10104. P. 1770–1780. doi: 10.1016/S0140-6736(17)31002-4</mixed-citation></citation-alternatives></ref><ref id="B3"><label>3.</label><citation-alternatives><mixed-citation xml:lang="en">Kalashnikova AA, Voroshilova TM. Evaluation of CD64 expression by blood neutrophils in the diagnosis of bacterial infections and sepsis. Handbook of the head of CDL. 2016;5:44–54. EDN WCKTVF (In Russ.)</mixed-citation><mixed-citation xml:lang="ru">Калашникова А.А., Ворошилова Т.М. Оценка экспрессии CD64 нейтрофилами крови в диагностике бактериальных инфекций и сепсиса // Справочник заведующего КДЛ. 2016. № 5. С. 44–54. EDN: WCKTVF</mixed-citation></citation-alternatives></ref><ref id="B4"><label>4.</label><citation-alternatives><mixed-citation xml:lang="en">Eichberger J, Resch E, Resch B. Diagnosis of neonatal sepsis: the role of inflammatory markers. Front Pediatr. 2022;10:840288. doi: 10.3389/fped.2022.840288</mixed-citation><mixed-citation xml:lang="ru">Eichberger J., Resch E., Resch B. Diagnosis of neonatal sepsis: the role of inflammatory markers // Front Pediatr. 2022. Vol. 10. P. 840288. doi: 10.3389/fped.2022.840288</mixed-citation></citation-alternatives></ref><ref id="B5"><label>5.</label><citation-alternatives><mixed-citation xml:lang="en">Muhin VE, Pankrat’eva LL, Yarcev MN, Volodin NN. Developmental adaptations of neonatal neutrophils (review). Russian Journal of Allergy. 2021;18(2):55–65. EDN: DQEFLW. doi: 10.36691/RJA1438</mixed-citation><mixed-citation xml:lang="ru">Мухин В.Е., Панкратьева Л.Л., Ярцев М.Н., Володин Н.Н. Особенности онтогенетической адаптации нейтрофилов новорожденного (обзор литературы) // Российский аллергологический журнал. 2021. Т. 18, № 2. С. 55–65. EDN: DQEFLW doi: 10.36691/RJA1438</mixed-citation></citation-alternatives></ref><ref id="B6"><label>6.</label><citation-alternatives><mixed-citation xml:lang="en">Patent RU No. 2374646/ 27.11.09. Byul. No. 33. Dudareva MV, Lelik MP, Puhtinskaya MG. Method of early diagnosis of neonatal sepsis development in newborns with respiratory distress syndrome and hypoxic CNS damage. (In Russ.) [cited 2024 Aug 14]. Available from: https://patents.google.com/patent/RU2374646C1/ru</mixed-citation><mixed-citation xml:lang="ru">Патент РФ на изобретение № 2374646/ 27.11.09. Бюл. №33. Дударева М.В., Лелик М.П., Пухтинская М.Г. Способ ранней диагностики развития неонатального сепсиса у новорожденных с синдромом дыхательных расстройств и гипоксическим поражением ЦНС. Режим доступа: https://patents.google.com/patent/RU2374646C1/ru Дата обращения: 14.08.2024.</mixed-citation></citation-alternatives></ref><ref id="B7"><label>7.</label><citation-alternatives><mixed-citation xml:lang="en">Obraztsov IV, Obraztsova AA, Voronina OV, et al. Prediction of infectious and septic processes in newborns using the study of CD10 and CD16 neutrophils [proceedings] In: Collection of studies of young scientists competition in the framework of the conference “Current issues and innovative technologies in anesthesiology and resuscitation” (2024 April 5–6, Saint Petersburg). 2024. P. 10–14.</mixed-citation><mixed-citation xml:lang="ru">Образцов И.В., Образцова А.А., Воронина О.В., и др. Прогнозирование инфекционно-септических процессов у новорожденных при помощи исследования CD10 и CD16 нейтрофилов [тезисы]. В кн.: Сборник работ конкурса молодых ученых научно-образовательной конференции «Актуальные вопросы и инновационные технологии в анестезиологии и реаниматологии» (5–6 апреля 2024 г., Санкт-Петербург). 2024. С. 10–14</mixed-citation></citation-alternatives></ref><ref id="B8"><label>8.</label><citation-alternatives><mixed-citation xml:lang="en">Elghetany MT. Surface antigen changes during normal neutrophilic development: a critical review. Blood Cells Mol Dis. 2002;28(2):260–274. doi: 10.1006/bcmd.2002.0513</mixed-citation><mixed-citation xml:lang="ru">Elghetany M.T. Surface antigen changes during normal neutrophilic development: a critical review // Blood Cells Mol Dis. 2002. Vol. 28, N 2. P. 260–274. doi: 10.1006/bcmd.2002.0513</mixed-citation></citation-alternatives></ref><ref id="B9"><label>9.</label><citation-alternatives><mixed-citation xml:lang="en">Marini O, Costa S, Bevilacqua D, et al. Mature CD10+ and immature CD10– neutrophils present in G-CSF-treated donors display opposite effects on T cells [published correction appears in Blood. 2017;129(24):3271. doi: 10.1182/blood-2017-05-783423]. Blood. 2017;129(10):1343–1356. doi: 10.1182/blood-2016-04-713206</mixed-citation><mixed-citation xml:lang="ru">Marini O., Costa S., Bevilacqua D., et al. Mature CD10+ and immature CD10– neutrophils present in G-CSF-treated donors display opposite effects on T cells [published correction appears in Blood. 2017. Vol. 129, N 24. P. 3271. doi: 10.1182/blood-2017-05-783423] // Blood. 2017. Vol. 129, N 10. P. 1343–1356. doi: 10.1182/blood-2016-04-713206</mixed-citation></citation-alternatives></ref><ref id="B10"><label>10.</label><citation-alternatives><mixed-citation xml:lang="en">Meng Y, Ye F, Nie P, et al. Immunosuppressive CD10+ALPL+ neutrophils promote resistance to anti-PD-1 therapy in HCC by mediating irreversible exhaustion of T cells. J Hepatol. 2023;79(6):1435–1449. doi: 10.1016/j.jhep.2023.08.024</mixed-citation><mixed-citation xml:lang="ru">Meng Y., Ye F., Nie P., et al. Immunosuppressive CD10+ALPL+ neutrophils promote resistance to anti-PD-1 therapy in HCC by mediating irreversible exhaustion of T cells // J Hepatol. 2023. Vol. 79, N 6. P. 1435–1449. doi: 10.1016/j.jhep.2023.08.024</mixed-citation></citation-alternatives></ref><ref id="B11"><label>11.</label><citation-alternatives><mixed-citation xml:lang="en">Kaneko T, Stearns-Kurosawa DJ, Taylor FJr, et al. Reduced neutrophil CD10 expression in nonhuman primates and humans after in vivo challenge with E. coli or lipopolysaccharide. Shock. 2003;20(2):130–137. doi: 10.1097/01.shk.0000068326.68761.34</mixed-citation><mixed-citation xml:lang="ru">Kaneko T., Stearns-Kurosawa D.J., Taylor F.Jr., et al. Reduced neutrophil CD10 expression in nonhuman primates and humans after in vivo challenge with E. coli or lipopolysaccharide // Shock. 2003. Vol. 20, N 2. P. 130–137. doi: 10.1097/01.shk.0000068326.68761.34</mixed-citation></citation-alternatives></ref><ref id="B12"><label>12.</label><citation-alternatives><mixed-citation xml:lang="en">Liu M, Wang G, Wang L, et al. Immunoregulatory functions of mature CD10+ and immature CD10– neutrophils in sepsis patients. Front Med (Lausanne). 2023;9:1100756. doi: 10.3389/fmed.2022.1100756</mixed-citation><mixed-citation xml:lang="ru">Liu M., Wang G., Wang L., et al. Immunoregulatory functions of mature CD10+ and immature CD10– neutrophils in sepsis patients // Front Med (Lausanne). 2023. Vol. 9. P. 1100756. doi: 10.3389/fmed.2022.1100756</mixed-citation></citation-alternatives></ref><ref id="B13"><label>13.</label><citation-alternatives><mixed-citation xml:lang="en">Liu J, Shi H, Yu J, Xiong J. CD10 is a good biomarker to predict bacterial infection in sepsis-suspected patients. Acta Med Mediterr. 2019;35:2851. doi: 10.19193/0393-6384_2019_5_448</mixed-citation><mixed-citation xml:lang="ru">Liu J., Shi H., Yu J., Xiong J. CD10 is a good biomarker to predict bacterial infection in sepsis-suspected patients // Acta Med Mediterr. 2019. Vol. 35. P. 2851. doi: 10.19193/0393-6384_2019_5_448</mixed-citation></citation-alternatives></ref><ref id="B14"><label>14.</label><citation-alternatives><mixed-citation xml:lang="en">Muhin VE, Praulova DA, Pankrat’eva LL. Expression of Fc-gamma receptors of neutrophils in premature infants of different gestational ages. Current Pediatrics. 2016;15(3):273–278. EDN: WHHHTH doi: 10.15690/vsp.v15i3.1565</mixed-citation><mixed-citation xml:lang="ru">Мухин В.Е., Праулова Д.А., Панкратьева Л.Л., и др. Экспрессия Fc-gamma рецепторов нейтрофилов у недоношенных детей различного гестационного возраста // Вопросы современной педиатрии. 2016. Т. 15, № 3. С. 273–278. EDN: WHHHTH doi: 10.15690/vsp.v15i3.1565</mixed-citation></citation-alternatives></ref><ref id="B15"><label>15.</label><citation-alternatives><mixed-citation xml:lang="en">Lakschevitz FS, Hassanpour S, Rubin A, et al. Identification of neutrophil surface marker changes in health and inflammation using high-throughput screening flow cytometry. Exp Cell Res. 2016;342(2):200–209. doi: 10.1016/j.yexcr.2016.03.007</mixed-citation><mixed-citation xml:lang="ru">Lakschevitz F.S., Hassanpour S., Rubin A., et al. Identification of neutrophil surface marker changes in health and inflammation using high-throughput screening flow cytometry // Exp Cell Res. 2016. Vol. 342, N 2. P. 200–209. doi: 10.1016/j.yexcr.2016.03.007</mixed-citation></citation-alternatives></ref><ref id="B16"><label>16.</label><citation-alternatives><mixed-citation xml:lang="en">Medara N, Lenzo JC, Walsh KA, et al. Peripheral neutrophil phenotypes during management of periodontitis. J Periodontal Res. 2021;56(1):58–68. doi: 10.1111/jre.12793</mixed-citation><mixed-citation xml:lang="ru">Medara N., Lenzo J.C., Walsh K.A., et al. Peripheral neutrophil phenotypes during management of periodontitis // J Periodontal Res. 2021. Vol. 56, N 1. P. 58–68. doi: 10.1111/jre.12793</mixed-citation></citation-alternatives></ref><ref id="B17"><label>17.</label><citation-alternatives><mixed-citation xml:lang="en">Fraser JA, Kemp S, Young L, et al. Silver nanoparticles promote the emergence of heterogeneic human neutrophil sub-populations. Sci Rep. 2018;8(1):7506. doi: 10.1038/s41598-018-25854-2</mixed-citation><mixed-citation xml:lang="ru">Fraser J.A., Kemp S., Young L., et al. Silver nanoparticles promote the emergence of heterogeneic human neutrophil sub-populations // Sci Rep. 2018. Vol. 8, N 1. P. 7506. doi: 10.1038/s41598-018-25854-2</mixed-citation></citation-alternatives></ref><ref id="B18"><label>18.</label><citation-alternatives><mixed-citation xml:lang="en">Zhang J, Gao C, Zhu Z, et al. New findings on CD16brightCD62Ldim neutrophil subtypes in sepsis-associated ARDS: an observational clinical study. Front Immunol. 2024;15:1331050. doi: 10.3389/fimmu.2024.1331050</mixed-citation><mixed-citation xml:lang="ru">Zhang J., Gao C., Zhu Z., et al. New findings on CD16brightCD62Ldim neutrophil subtypes in sepsis-associated ARDS: an observational clinical study // Front Immunol. 2024. Vol. 15. P. 1331050. doi: 10.3389/fimmu.2024.1331050</mixed-citation></citation-alternatives></ref><ref id="B19"><label>19.</label><citation-alternatives><mixed-citation xml:lang="en">Dransfield I, Buckle AM, Savill JS, et al. Neutrophil apoptosis is associated with a reduction in CD16 (Fc gamma RIII) expression. J Immunol. 1994;153(3):1254–1263.</mixed-citation><mixed-citation xml:lang="ru">Dransfield I., Buckle A.M., Savill J.S., et al. Neutrophil apoptosis is associated with a reduction in CD16 (Fc gamma RIII) expression// J Immunol. 1994. Vol. 153, N 3. P. 1254–1263.</mixed-citation></citation-alternatives></ref><ref id="B20"><label>20.</label><citation-alternatives><mixed-citation xml:lang="en">Lu Y, Huang Y, Huang L, et al. CD16 expression on neutrophils predicts treatment efficacy of capecitabine in colorectal cancer patients. BMC Immunol. 2020;21(1):46. doi: 10.1186/s12865-020-00375-8</mixed-citation><mixed-citation xml:lang="ru">Lu Y., Huang Y., Huang L., et al. CD16 expression on neutrophils predicts treatment efficacy of capecitabine in colorectal cancer patients // BMC Immunol. 2020. Vol. 21, N 1. P. 46. doi: 10.1186/s12865-020-00375-8</mixed-citation></citation-alternatives></ref><ref id="B21"><label>21.</label><citation-alternatives><mixed-citation xml:lang="en">Butcher SK, Chahal H, Nayak L, et al. Senescence in innate immune responses: reduced neutrophil phagocytic capacity and CD16 expression in elderly humans. J Leukoc Biol. 2001;70(6):881–886.</mixed-citation><mixed-citation xml:lang="ru">Butcher S.K., Chahal H., Nayak L., et al. Senescence in innate immune responses: reduced neutrophil phagocytic capacity and CD16 expression in elderly humans // J Leukoc Biol. 2001. Vol. 70, N 6. P. 881–886.</mixed-citation></citation-alternatives></ref></ref-list></back></article>
